Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
American Pharma SummitAmerican Pharma Summit
Not Confirmed
Not Confirmed
18-19 November, 2024
Pharma Manufacturing 2...Pharma Manufacturing 2024
Not Confirmed
Not Confirmed
18-19 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
American Pharma SummitAmerican Pharma Summit
Industry Trade Show
Not Confirmed
18-19 November, 2024
Pharma Manufacturing 2...Pharma Manufacturing 2024
Industry Trade Show
Not Confirmed
18-19 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/medical-breakthroughs-in-2024-alzheimer-s-schizophrenia-copd-mash-see-pathbreaking-treatments
29 Aug 2024
// REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/neurocrines-schizophrenia-drug-meets-main-goal-mid-stage-study-2024-08-28/
09 Apr 2024
// James Waldron FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/karunas-captains-set-sail-new-neuropsychiatric-venture-called-seaport-therapeutics
18 Mar 2024
// BUSINESSWIRE
13 Mar 2024
// PRESS RELEASE
https://in.investing.com/news/karuna-therapeutics-set-to-merge-with-bristolmyers-squibb-93CH-4068675#:~:text=Upon%20completion%2C%20Karuna%20will%20operate,rheumatoid%20arthritis%2C%20and%20psychiatric%20disorders.
01 Mar 2024
// Gabrielle Masson FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/response-shareholder-lawsuit-karuna-vigorously-denies-wrongdoing-and-provides-further-info
22 Feb 2024
// BUSINESSWIRE
Details:
BMS acquires KarXT (xanomeline-trospium), an M1/M4 receptor agonist, for treating schizophrenia, enhancing its development.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: KarXT
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Bristol Myers Squibb
Deal Size: $14,000.0 million Upfront Cash: $14,000.0 million
Deal Type: Acquisition March 18, 2024
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Bristol Myers Squibb
Deal Size : $14,000.0 million
Deal Type : Acquisition
Bristol Myers Squibb Completes Acquisition Of Karuna Therapeutics for $14 Billion
Details : BMS acquires KarXT (xanomeline-trospium), an M1/M4 receptor agonist, for treating schizophrenia, enhancing its development.
Brand Name : KarXT
Molecule Type : Small molecule
Upfront Cash : $14,000.0 million
March 18, 2024
Details:
Through the acquisition, BMS will enhance the development of KarXT (xanomeline-trospium), an antipsychotic with a novel mechanism of being a first-in-class M1 / M4 muscarinic receptor agonist, with differentiated efficacy and safety for treating schizophrenia in adults.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: KarXT
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Bristol Myers Squibb
Deal Size: $14,000.0 million Upfront Cash: $14,000.0 million
Deal Type: Acquisition December 22, 2023
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Bristol Myers Squibb
Deal Size : $14,000.0 million
Deal Type : Acquisition
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
Details : Through the acquisition, BMS will enhance the development of KarXT (xanomeline-trospium), an antipsychotic with a novel mechanism of being a first-in-class M1 / M4 muscarinic receptor agonist, with differentiated efficacy and safety for treating schizoph...
Brand Name : KarXT
Molecule Type : Small molecule
Upfront Cash : $14,000.0 million
December 22, 2023
Details:
KarXT (xanomeline and trospium chloride) is an M1/M4 receptor Agonist small molecule drug delivered orally in capsule form for the treatment of Schizophrenia.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: KarXT
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2023
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : KarXT (xanomeline and trospium chloride) is an M1/M4 receptor Agonist small molecule drug delivered orally in capsule form for the treatment of Schizophrenia.
Brand Name : KarXT
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 29, 2023
Details:
KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: KarXT
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2023
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease.
Brand Name : KarXT
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 17, 2023
Details:
KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: KarXT
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2023
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease.
Brand Name : KarXT
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 16, 2023
Details:
KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: KarXT
Study Phase: Phase IIIProduct Type: Small molecule
Recipient: PureTech Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2023
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Recipient : PureTech Health
Deal Size : Not Applicable
Deal Type : Not Applicable
KarXT, invented at PureTech, submitted for FDA Approval in Schizophrenia
Details : KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease.
Brand Name : KarXT
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 28, 2023
Details:
The proceedings will be used to fund Karuna's ongoing and planned clinical trials of KarXT (xanomeline), to support the potential commercialization of KarXT for psychosis in schizophrenia, to support and expand company's pipeline of clinical and preclinical programs.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: KarXT
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Goldman Sachs & Co. LLC
Deal Size: $460.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 24, 2023
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Goldman Sachs & Co. LLC
Deal Size : $460.0 million
Deal Type : Public Offering
Details : The proceedings will be used to fund Karuna's ongoing and planned clinical trials of KarXT (xanomeline), to support the potential commercialization of KarXT for psychosis in schizophrenia, to support and expand company's pipeline of clinical and preclini...
Brand Name : KarXT
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 24, 2023
Details:
Under the agreement, Royalty Pharma will acquire PureTech’s royalty in Karuna’s KarXT (xanomeline), an oral, investigational M1/M4-preferring muscarinic agonist for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: KarXT
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Royalty Pharma
Deal Size: $500.0 million Upfront Cash: $100.0 million
Deal Type: Agreement March 23, 2023
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Royalty Pharma
Deal Size : $500.0 million
Deal Type : Agreement
PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million
Details : Under the agreement, Royalty Pharma will acquire PureTech’s royalty in Karuna’s KarXT (xanomeline), an oral, investigational M1/M4-preferring muscarinic agonist for the treatment of psychiatric and neurological conditions, including schizophrenia and...
Brand Name : KarXT
Molecule Type : Small molecule
Upfront Cash : $100.0 million
March 23, 2023
Details:
The proceedings will be used to fund Karuna's ongoing and planned clinical trials of KarXT (xanomeline), to support the potential commercialization of KarXT for psychosis in schizophrenia, to support and expand company's pipeline of clinical and preclinical programs.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: KarXT
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Goldman Sachs & Co. LLC
Deal Size: $400.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 21, 2023
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Goldman Sachs & Co. LLC
Deal Size : $400.0 million
Deal Type : Public Offering
Karuna Therapeutics Announces Pricing of Public Offering of Common Stock
Details : The proceedings will be used to fund Karuna's ongoing and planned clinical trials of KarXT (xanomeline), to support the potential commercialization of KarXT for psychosis in schizophrenia, to support and expand company's pipeline of clinical and preclini...
Brand Name : KarXT
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 21, 2023
Details:
KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: KarXT
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2023
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease.
Brand Name : KarXT
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 20, 2023
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?